|LGNZZ -- USA Stock|| |
USD 0.12 0.001 0.83%
LIGAND PHARM holds performance score of 10 on a scale of zero to a hundred. The company secures Beta (Market Risk) of -0.2066 which conveys that as returns on market increase, returns on owning LIGAND PHARM are expected to decrease at a much smaller rate. During bear market, LIGAND PHARM is likely to outperform the market.. Although it is vital to follow to LIGAND PHARM INC price patterns
, it is good to be conservative about what you can actually do with the information regarding equity historical price patterns
. Macroaxis philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators
. To evaluate if LIGAND PHARM expected return of 1.2199 will be sustainable into the future, we have found twenty-one different technical indicators
which can help you to check if the expected returns are sustainable. Use LIGAND PHARM INC Standard Deviation
, Value At Risk
, as well as the relationship
between Jensen Alpha
and Semi Variance
to analyze future returns on LIGAND PHARM INC.
LIGAND PHARM INC Relative Risk vs. Return Landscape
If you would invest 8.20
in LIGAND PHARM INC on November 15, 2018
and sell it today you would earn a total of 3.80
from holding LIGAND PHARM INC or generate 46.34%
return on investment over 30
days. LIGAND PHARM INC is currently producing 1.2199% returns and takes up 8.0249% volatility of returns over 30 trading days. Put another way, 72% of traded equities are less volatile than the company and 77% of traded equity instruments are likely to generate higher returns over the next 30 trading days.
Daily Expected Return (%)
Assuming 30 trading days horizon, LIGAND PHARM INC is expected to generate 6.29 times more return on investment than the market. However, the company is 6.29 times more volatile than its market benchmark. It trades about 0.15 of its potential returns per unit of risk. The DOW is currently generating roughly -0.11 per unit of risk.
LIGAND PHARM Market Risk Analysis
Sharpe Ratio = 0.152
LIGAND PHARM Relative Performance Indicators
Estimated Market Risk
| || |
| || |
| || |
Based on monthly moving average LIGAND PHARM is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LIGAND PHARM
by adding it to a well-diversified
Compared to the overall equity markets, risk-adjusted returns on investments in LIGAND PHARM INC are ranked lower than 10 (%) of all global equities and portfolios over the last 30 days.